Patents by Inventor Michael Tesar

Michael Tesar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110165170
    Abstract: The present disclosure provides isolated antibodies, particularly human antibodies, or antigen binding portions thereof, that bind to osteopontin with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-osteopontin antibodies or antigen binding portions thereof described herein.
    Type: Application
    Filed: August 19, 2010
    Publication date: July 7, 2011
    Applicant: Pfizer Inc.
    Inventors: Trisha Ann Haubrich, Justin Thomas Bingham, Jitesh Pranial Jani, Alessandra Blasina, Kathrin Ladetzki-Baehs, Michael Tesar, Justin Guy Chapman, Dirk Ponsel, Michael A. North
  • Publication number: 20100285004
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: February 7, 2005
    Publication date: November 11, 2010
    Inventors: Michael Tesar, Ute Jager
  • Publication number: 20090325290
    Abstract: The present invention relates to polypeptide compositions which bind to cell surface epitopes and, in multivalent forms, cause or lead to the killing of cells including lymphoid tumor cells, and in the case of monovalent forms, cause immunosuppression or otherwise inhibit activation of lymphocytes. The invention further relates to nucleic acids encoding the polypeptides, methods for the production of the polypeptides, methods for killing cells, methods for immunosuppressing a patient, pharmaceutical, diagnostic and multivalent compositions and kits comprising the polypeptides and uses of the polypeptides.
    Type: Application
    Filed: April 20, 2009
    Publication date: December 31, 2009
    Inventors: Zoltan Nagy, Christoph Brunner, Michael Tesar, Elisabeth Thomassen Wolf, Robert Rauchenberger
  • Publication number: 20090252733
    Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.
    Type: Application
    Filed: October 12, 2006
    Publication date: October 8, 2009
    Applicant: MORPHOSYS AG
    Inventor: Michael Tesar
  • Publication number: 20090123950
    Abstract: The present invention provides novel methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.
    Type: Application
    Filed: May 24, 2006
    Publication date: May 14, 2009
    Applicant: MORPHOSYS AG
    Inventor: Michael Tesar
  • Patent number: 7521047
    Abstract: The present invention relates to polypeptide compositions which bind to cell surface epitopes and, in multivalent forms, cause or lead to the killing of cells including lymphoid tumor cells, and in the case of monovalent forms, cause immunosuppression or otherwise inhibit activation of lymphocytes. The invention further relates to nucleic acids encoding the polypeptides, methods for the production of the polypeptides, methods for killing cells, methods for immunosuppressing a patient, pharmaceutical, diagnostic and multivalent compositions and kits comprising the polypeptides and uses of the polypeptides.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: April 21, 2009
    Assignees: GPC Biotech AG, Morphosys AG
    Inventors: Zoltan Nagy, Christoph Brunner, Michael Tesar, Elisabeth Thomassen-Wolf, Robert Rauchenberger
  • Publication number: 20050260103
    Abstract: A control system for a regenerative thermal oxidizer in which contaminated air is first passed through a hot heat-exchange bed and into a communicating high temperature oxidation (combustion) chamber, and then through a relatively cool second heat exchange bed. The apparatus includes a number of internally insulated, ceramic filled heat recovery columns topped by an internally insulated combustion chamber. Contaminated air is directed into heat exchange media in one of said columns, and oxidation is completed as the flow passes through the combustion chamber. From the combustion chamber, the now clean air flows through another column containing heat exchange media, thereby storing heat in the media for use in a subsequent inlet cycle when the flow control valves reverse. The resulting clean air is directed via an outlet valve through an outlet manifold and released to atmosphere or is recirculated back to the oxidizer inlet.
    Type: Application
    Filed: December 7, 2001
    Publication date: November 24, 2005
    Inventors: Michael Tesar, Andreas Ruhl, Steven Zagar
  • Publication number: 20040019187
    Abstract: The present invention relates to human polypeptides causing or leading to the modulation of the immune system. The invention further relates to nucleic acids encoding the polypeptides, methods for production of the polypeptides, methods for immunosuppression, pharmaceutical and diagnostic compositions and kits comprising the polypeptides and uses of the polypeptides.
    Type: Application
    Filed: April 23, 2003
    Publication date: January 29, 2004
    Inventors: Zoltan Nagy, Michael Tesar, Elisabeth Thomassen-Wolf
  • Publication number: 20030032782
    Abstract: The present invention relates to polypeptide compositions which bind to cell surface epitopes and, in multivalent forms, cause or lead to the killing of cells including lymphoid tumor cells, and in the case of monovalent forms, cause immunosuppression or otherwise inhibit activation of lymphocytes. The invention further relates to nucleic acids encoding the polypeptides, methods for the production of the polypeptides, methods for killing cells, methods for immunosuppressing a patient, pharmaceutical, diagnostic and multivalent compositions and kits comprising the polypeptides and uses of the polypeptides.
    Type: Application
    Filed: November 15, 2001
    Publication date: February 13, 2003
    Inventors: Zoltan Nagy, Christoph Brunner, Michael Tesar, Elisabeth Thomassen Wolf